Atria Wealth Solutions Inc. Purchases 389 Shares of Stryker Co. (NYSE:SYK)

Atria Wealth Solutions Inc. raised its position in Stryker Co. (NYSE:SYK) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,607 shares of the medical technology company’s stock after buying an additional 389 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Stryker were worth $5,987,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in SYK. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $36,000. Activest Wealth Management bought a new stake in shares of Stryker during the 4th quarter valued at $36,000. Crews Bank & Trust bought a new stake in shares of Stryker during the 4th quarter valued at $39,000. Finally, Hara Capital LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.7 %

Shares of NYSE:SYK opened at $388.30 on Thursday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The firm has a market capitalization of $148.17 billion, a P/E ratio of 50.04, a P/E/G ratio of 2.90 and a beta of 0.96. The stock has a 50 day moving average price of $377.69 and a 200-day moving average price of $368.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

SYK has been the subject of several recent analyst reports. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Finally, Barclays boosted their target price on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.